Bacterial enoyl-acyl carrier protein (ACP) reductases (FabI and FabK) catalyze the final step in each cycle of bacterial fatty acid biosynthesis and are attractive targets for the development of new antibacterial agents. Here, we report the development of novel FabK inhibitors with antibacterial activity against Streptococcus pneumoniae. Based on structure-activity relationship (SAR) studies of our screening hits, we have developed novel phenylimidazole derivatives as potent FabK inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.
MAHMOUD A. M.; EL-SHERIEF H. A.; ABDEL-RAHMAN A. E., EUR. J. MED. CHEM.-CHIM. THER., 1981, 16, NO 4, 383-384
作者:MAHMOUD A. M.、 EL-SHERIEF H. A.、 ABDEL-RAHMAN A. E.
DOI:——
日期:——
Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK
Novel FabK inhibitors with antibacterial activity against Streptococcus pneuinoniae were synthesized and evaluated. Through SAR studies of our initial hit compound 2-(1H-benz[d]imidazol-2-ylthio)-N-(6-methoxycarbonylbenzo[d]thiazo1-2-yl)acetamide, a series of novel phenylimidazole derivatives were discovered as potent FabK inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.